SAN DIEGO and KALAMAZOO, Mich., March 27, 2019 /PRNewswire/ -- Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that it will present preclinical data supporting the importance of the unique mechanism of action of its lead drug candidate for NASH at The International Liver Congress™ 2019, occurring in Vienna, Austria, from April 10-14, 2019, at the Reed Messe Wien Exhibition & Congress Center.
The presentations are as follows:
Title: Effect on MSDC-0602K treatment on the metabolome of a diet-induced murine model. (Abstract FRI-289) Date: April 12 Time 9 a.m. to 5 p.m. CET
Title: MSDC-0602K, a PPAR-gamma sparing modulator of the mitochondrial pyruvate carrier, improves NASH outcome in a diet-induced animal model of non-alcoholic steatohepatitis. (Abstract PS-135) Date: April 13 Time: 9:30 a.m. CET
Title: MSDC-0602K targets the mitochondrial pyruvate carrier to treat non-alcoholic steatohepatitis. (Abstract SAT-344) Date: April 13 Time: 9 a.m. to 5 p.m. CET
About Cirius Therapeutics Cirius is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. Our lead product candidate, MSDC-0602K, is a novel small molecule being developed as a once-daily oral therapy to treat NASH with fibrosis. MSDC-0602K is designed to selectively modulate the mitochondrial pyruvate carrier (MPC), which mediates at the cellular level the effects of overnutrition, a major cause of NASH and other metabolic disorders. We are conducting a Phase 2b clinical trial of MSDC-0602K, which we have fully enrolled with 402 patients diagnosed with NASH with fibrosis.